Literature DB >> 17164040

Neurointerventional treatment of vasospasm.

Jonathan L Brisman1, Joseph M Eskridge, David W Newell.   

Abstract

OBJECTIVES: To review the historical development and current status of endovascular techniques used in the treatment of symptomatic vasospasm following aneurysmal subarachnoid hemorrhage.
METHODS: This article summarizes the relevant literature on neurointerventional therapy for vasospasm, namely instillation of intraarterial medication (papaverine, nicardipine, verapamil) and transluminal balloon angioplasty. The authors synthesize the available literature with their own experience using the various endovascular modalities to treat vasospasm at high volume cerebrovascular centers. TECHNIQUE: Indications for the use of neurointerventional therapy as well as a summary of the technique for transluminal angioplasty to treat vasospasm as employed by the authors is described. DISCUSSION: Neurointerventional treatment of vasospasm following aneurysmal hemorrhage has been proven to be a safe and successful technique for those patients suffering symptomatic vasospasm refractory to medical management. The techniques contunue to undergo refinement as endovascular technology advances. We currently favor the use of balloon angioplasty over intraarterial antispasmotics due to the increased durability and long-lasting effects of the former and lower risk profile.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17164040     DOI: 10.1179/016164106X152043

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  9 in total

1.  In vivo therapeutic gas delivery for neuroprotection with echogenic liposomes.

Authors:  George L Britton; Hyunggun Kim; Patrick H Kee; Jaroslaw Aronowski; Christy K Holland; David D McPherson; Shao-Ling Huang
Journal:  Circulation       Date:  2010-10-04       Impact factor: 29.690

Review 2.  Management of aneurysmal subarachnoid hemorrhage.

Authors:  Michael N Diringer
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

3.  Continuous selective intraarterial infusion of nimodipine for therapy of refractory cerebral vasospasm.

Authors:  S Wolf; H Martin; J F Landscheidt; S O Rodiek; L Schürer; C B Lumenta
Journal:  Neurocrit Care       Date:  2010-06       Impact factor: 3.210

4.  Role of calcitonin gene-related peptide in cerebral vasospasm, and as a therapeutic approach to subarachnoid hemorrhage.

Authors:  Stelios Kokkoris; Peter Andrews; David J Webb
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-15       Impact factor: 5.555

5.  Comparative transcriptome analysis using high papaverine mutant of Papaver somniferum reveals pathway and uncharacterized steps of papaverine biosynthesis.

Authors:  Sumya Pathak; Deepika Lakhwani; Parul Gupta; Brij Kishore Mishra; Sudhir Shukla; Mehar Hasan Asif; Prabodh Kumar Trivedi
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

Review 6.  Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage.

Authors:  Salah G Keyrouz; Michael N Diringer
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

7.  Continuous Local Intra-Arterial Nimodipine for the Treatment of Cerebral Vasospasm.

Authors:  Nicola Logallo; Marianne Lundervik Bøthun; Anne Berit Guttormsen; Gunhild Holmaas; Jostein Kråkenes; Lars Thomassen; Frode Svendsen; Christian A Helland
Journal:  J Neurol Surg Rep       Date:  2015-03-04

8.  Continuous selective intra-arterial application of nimodipine in refractory cerebral vasospasm due to aneurysmal subarachnoid hemorrhage.

Authors:  Stephanie Ott; Sheila Jedlicka; Stefan Wolf; Mozes Peter; Christine Pudenz; Patrick Merker; Ludwig Schürer; Christianto Benjamin Lumenta
Journal:  Biomed Res Int       Date:  2014-01-16       Impact factor: 3.411

Review 9.  Clinical and experimental aspects of aneurysmal subarachnoid hemorrhage.

Authors:  Badih J Daou; Sravanthi Koduri; B Gregory Thompson; Neeraj Chaudhary; Aditya S Pandey
Journal:  CNS Neurosci Ther       Date:  2019-10       Impact factor: 5.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.